‘Great negotiating!’ Pfizer contract with Brazil reveals EU paid more than double for jab

Pfizer coronavirus vaccine approved for 12 to 15 year olds

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

The EU has agreed to a deal for an additional 900 million doses of the BioNTech/Pfizer vaccine, with the option to purchase another 900 million. The pharmaceutical company said that this is the “largest supply contract in the history of the pharmaceutical industry.”

The deal is meant to ensure that the EU is able to provide booster shots.

The German biotech firm said that offering a third dose of its established two-shot vaccine remained the best response to concerns over waning immune protection in the face of the highly contagious Delta variant, as worse strains may emerge.

BioNTech said the more than one billion supply tally as per July 21 was up from the 700 million-plus doses it announced in June.

But the German pharmaceutical company upped the price of its antidote for the EU to €19.50 per dose ($23.15).

The huge price hike infuriated Generation Frexit leader Charles-Henri Gallois when a contract for more doses of the vaccine between Pfizer and Brazil was made public.

According to the agreement, Jair Bolsonaro’s government will pay just $10 per dose, more than half the price agreed with Brussels.

Commenting on the news, Mr Gallois said: “Another great negotiation by the EU!”

Based on delivery contracts signed for more than 2.2 billion doses so far, BioNTech said in a statement detailing its second-quarter earnings that it expects to accrue 15.9 billion euros in revenue from the vaccine this year, up from a May forecast of 12.4 billion euros.

That includes sales, milestone payments and a share of gross profit in its partners’ territories, BioNTech added.

Pfizer late last month raised its forecast for its share of 2021 vaccine sales to $33.5 billion and said at the time it believes people will need a third dose of the shot.

Pfizer and BioNTech’s decision in early July to seek authorisation for a third dose drew criticism from US health regulators, who said there was not yet enough data to show booster shots are needed.

US health agencies have since discussed additional doses for people with compromised immune systems, while Germany and France said they would roll out a third dose for the most vulnerable from September.

That jars with a call by the World Health Organisation to use doses instead to jump-start vaccination campaigns in poorer nations that have so far been left behind.

DON’T MISS:
Vaccinated breast milk may offer protection against COVID-19 – study [DATA]
Covid threat: Rise of mutant New York variant alarms scientists [INSIGHT]
Vaccine passports have been a failure in EU, says KAROL SIKORA [COMMENT]

BioNTech Chief Executive Ugur Sahin said that although work was ongoing to adjust the vaccine to variants it was not clear whether yet another version of the pathogen would supplant the now prevalent Delta variant.

“Making a decision at the moment might turn out to be wrong in three or six months if another variant is dominating,” Mr Sahin said during an analyst call.

Mr Tuereci said lab experiments had shown that a third shot of the established product generated neutralising antibodies against a range of strains and that the antibody boost was above the one following a second dose.

Still, the company reiterated plans to start testing a vaccine adjusted to the Delta variant on humans this month, part of a “comprehensive strategy to address variants”.

Source: Read Full Article